Barclays PLC Purchases 38,321 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Barclays PLC lifted its position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 70.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 92,651 shares of the biotechnology company’s stock after purchasing an additional 38,321 shares during the quarter. Barclays PLC’s holdings in Astria Therapeutics were worth $1,020,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Bank of New York Mellon Corp grew its holdings in Astria Therapeutics by 6.9% during the second quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock worth $1,266,000 after buying an additional 8,965 shares in the last quarter. Rhumbline Advisers boosted its holdings in Astria Therapeutics by 4.1% during the 2nd quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock worth $595,000 after acquiring an additional 2,556 shares during the last quarter. Quest Partners LLC grew its stake in shares of Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,112 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Astria Therapeutics by 1,043.7% in the second quarter. Dimensional Fund Advisors LP now owns 146,158 shares of the biotechnology company’s stock valued at $1,330,000 after purchasing an additional 133,379 shares during the last quarter. Finally, Sofinnova Investments Inc. bought a new position in shares of Astria Therapeutics during the second quarter valued at about $552,000. 98.98% of the stock is currently owned by institutional investors.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS opened at $7.37 on Wednesday. The firm has a fifty day moving average of $9.77 and a 200 day moving average of $10.69. Astria Therapeutics, Inc. has a 52-week low of $6.94 and a 52-week high of $16.90. The firm has a market capitalization of $415.92 million, a PE ratio of -3.53 and a beta of 0.70.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ATXS shares. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Monday. Oppenheimer upped their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.